Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough
Status and phase
Conditions
Treatments
Details and patient eligibility
About
This study is testing new ways to help people who have chronic cough that has not improved with typical treatments. One approach is called behavioral cough suppression (BCS) therapy, which teaches people techniques to stop themselves from coughing. Another approach uses capsaicin, the substance that makes chili peppers hot, to help reduce the body's sensitivity to cough triggers.
In this study, we will test three treatments:
- BCS therapy with capsaicin (BCS+CAP),
- BCS therapy with a placebo (BCS+Sham),
- Capsaicin stimulation alone (CAP).
We will enroll 150 adults with chronic cough and randomly assign them to one of the three treatments. Each person will attend 12 treatment sessions.
We want to find out how these treatments affect:
- How sensitive someone is to things that make them cough,
- How well they can hold back a cough when they try,
- How their brain responds to things that cause an urge-to-cough,
- And how much their coughing affects their quality of life.
We believe all treatments may reduce sensitivity to cough stimulants, but BCS treatments will also improve how people sense and control the urge to cough. We think combining BCS with capsaicin will work the best overall.
Full description
Refractory chronic cough (RCC) is a persistent and costly condition that is difficult to treat, often persisting despite appropriate treatment of underlying causes. While behavioral cough suppression (BCS) therapy has shown effectiveness in reducing cough frequency and improving quality of life in controlled studies, it remains underutilized, and the mechanisms by which it works are not well understood.
This multi-site randomized controlled trial will investigate the effects and mechanisms of BCS therapy with and without the addition of capsaicin desensitization, compared to capsaicin stimulation alone. Capsaicin, a known cough stimulant, has demonstrated desensitization effects on sensory pathways in conditions such as chronic rhinitis and pain syndromes, suggesting potential utility in modulating cough-related neural pathways.
We will recruit 150 participants diagnosed with RCC and randomize them into one of three treatment arms:
- BCS combined with capsaicin stimulation (BCS+CAP),
- BCS combined with sham stimulation (BCS+Sham),
- Capsaicin stimulation alone (CAP).
Participants will undergo 12 treatment sessions over several weeks. The study will evaluate both behavioral and neural markers of treatment response. Primary outcome measures will include:
- Cough sensory threshold (C5): the lowest concentration of citric acid causing five or more coughs,
- Cough suppression ability: the ability to suppress cough when instructed (the difference between the dose of capsaicin causing five or more coughs when trying to suppress cough (CS5) and C5,
- Urge-to-cough (UTC) sensory-motor threshold difference: a measure of how perception of the need to cough relates to actual coughing behavior,
- Blood oxygen level dependent (BOLD) neural responses using whole-brain functional MRI (fMRI) during UTC stimulation.
Secondary outcomes will include patient-reported measures such as the Leicester Cough Questionnaire (LCQ) and objective ambulatory cough frequency monitoring.
We hypothesize that all three treatments will lead to desensitization of cough sensitivity (i.e., increase in C5), but only the BCS-based interventions will alter UTC thresholds, suppression ability, and brain network activity. We further hypothesize that the combination of BCS and capsaicin (BCS+CAP) will provide the greatest therapeutic benefit due to simultaneous peripheral desensitization and central sensory-motor modulation.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Diagnosis of refractory or unexplained chronic cough
- Normal chest x-ray within past 2 years, without change in cough symptoms
- If diagnosed with asthma, is it well controlled
- Normal spirometry (or FEV1/FVC of at least 70% if diagnosed with asthma) within two years, without change in symptoms since
- Laryngoscopy or stroboscopy within 2 years without evidence of structural pathology and no change in vocal quality since exam
- Proficient reader/speaker of English
- Willing to take a pregnancy test before enrollment (if applicable)
- Willing to use contraception during the study (if applicable)
- Demonstrates understanding in study procedures and risks in order to consent
Exclusion criteria
- Currently a smoker of any substance
- Currently suffering from any signs of an upper respiratory infection (other than cough)
- Hemoptysis (coughing up blood)
- Pulmonary diagnosis other than asthma
- Used an ACE-inhibitor in the past 60 days
- Pregnant or trying to become pregnant
- Any complaints or clinical symptoms of dysphagia
- Live with or work with anyone with chronic cough
The following additional exclusion criteria will apply to participants at University of Colorado:
- Presence of metal implants, devices or fragments in the body
- Claustrophobia
Trial design
Primary purpose
Allocation
Interventional model
Masking
150 participants in 3 patient groups
Trial contacts and locations
Loading...
Central trial contact
Marie Jetté, PhD; Laurie J Slovarp, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal